NCT02440230已完成2 期
Safety of Ovarian Function Suppression(OFS)Combined With Different Aromatase Inhibitors(AIs) Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients：A Randomized, Controlled, Prospective, Observational Study
Shanghai Jiao Tong University School of Medicine1 个研究点 分布在 1 个国家目标入组 110 人开始时间: 2015年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 110
- 试验地点
- 1
- 主要终点
- Incidence of bone or joint pains
研究概览
简要总结
To compare safety of adjuvant OFS combined with anastrozole versus OFS combined with exemestane in Chinese premenopausal hormonal receptor(HR) positive breast cancer patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women aged ≥18 years;
- •Histologically confirmed invasive breast cancer by core needle biopsy or surgery,hormonal receptor positive, defined as estrogen receptor(ER)/progesterone receptor(PR) positive;
- •Premenopausal defined as
- •who have been menstruating regularly during the 6 months prior to randomization and have not used any form of hormonal contraception or any other hormonal treatments during the 6 months prior to randomization.
- •premenopausal status confirmed by an estradiol (E2) in the premenopausal range after chemotherapy related amenorrhea;
- •Patients must have received standard local therapy: normalized modified radical mastectomy or breast conserving surgery with negative margin and post-surgical radiotherapy. Patient should completed adjuvant therapy according to conditions, including adjuvant radiotherapy, neoadjuvant or adjuvant chemotherapy;
- •Patients who did not receive chemotherapy should be randomized within 24 weeks after definitive surgery.Patients who received prior adjuvant and/or neoadjuvant chemotherapy should be randomized after completing chemotherapy and within 8 months of the final dose of chemotherapy as soon as premenopausal status is confirmed;
- •Leukocyte ≥ 3*109/L; Platelets ≥ 75*109/L; Serum glutamate;
- •oxaloacetate(AST/SGOT) or serum glutamic-pyruvic transaminase(ALT/SGPT) <2.5 times of upper limit of normal (UNL) range;
- •Serum creatinine/blood urea nitrogen(BUN) ≤ upper limit of normal (UNL) range;
- •Written informed consent according to the local ethics committee requirements.
- •Has Eastern Cooperative Oncology Group(ECOG) Performance Score 0-2;
排除标准
- •Histologically confirmed hormonal receptor negative.
- •Post-menopausal.
- •Patients with inoperable local advanced breast cancer including inflammatory breast cancer or supraclavicular node involvement or with enlarged internal mammary nodes (unless pathologically negative).
- •Definitive surgery was done over 24 weeks before randomization for patients who did not receive chemotherapy.The final dose of chemotherapy was completed over 8 months before randomization for patients who received prior adjuvant and/or neoadjuvant chemotherapy.
- •Pregnant or lactating.
- •Patients with previous or concomitant invasive malignancy are not eligible. The exceptions are patients with the following (and only the following) malignancies (previous or concomitant) who are eligible if adequately treated: basal or squamous cell carcinoma of the skin in situ non-breast carcinoma without invasion contra- or ipsilateral in situ breast carcinoma non-breast invasive malignancy diagnosed at least 5 years ago and without recurrence:
- •stage I papillary thyroid cancer
- •stage Ia carcinoma of the cervix
- •stage Ia or b endometrioid endometrial cancer
- •borderline or stage I ovarian cancer
- •Patients who received endocrine therapy (including neoadjuvant and adjuvant) for more than 8 months after their breast cancer diagnosis.
- •Patients who were taking tamoxifen or other selective estrogen receptor modulator (SERM,e.g. Raloxifene) or hormone replacement therapy (HRT) within one year prior to their breast cancer diagnosis.
- •Patients who have had a bilateral oophorectomy or ovarian irradiation prior to their breast cancer diagnosis.
- •With severe hepatic dysfunction, Child-Pugh C.
- •With severe cardiac dysfunction, New York Heart Association (NYHA) grading III or worse.
- •Known severe hypersensitivity to any drugs in this study.
- •Participants of other experimental drug clinical trials
研究组 & 干预措施
OFS + Exemestane
Active Comparator
Patients who were anticipated to receive adjuvant OFS+AI endocrine therapy according to MDT discussion results were randomized to this arm,they will receive OFS+Exemestane.
干预措施: OFS + Exemestane (Drug)
OFS + Anastrozole
Experimental
Patients who were anticipated to receive adjuvant OFS+AI endocrine therapy according to MDT discussion results were randomized to this arm,they will receive OFS+Anastrozole.
干预措施: OFS + Anastrozole (Drug)
结局指标
主要结局
Incidence of bone or joint pains
时间窗: participants will be followed at 0,3,6,9,12 months from enrollment.
Bone and joint pains are measured by National Cancer Institute Common Toxicity Criteria for Adverse Effects (NCI CTCAE) classification v4.0 every 3 months.
次要结局
- peri-menapausal syndrome(KMI score)
研究者
Kunwei Shen
Professor
Shanghai Jiao Tong University School of Medicine
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
FACT anastrozole monotherapy versus maximal oestrogen blockade with anstrozole and fulvestrant combination therapy an open randomized, comparative, phase III multicentre study in postmenopausal women with hormone receptor positive breast cancer in first relapse after primary treatment of localized tumour. - FACTHormone Receptor Positive Advanced Breast CancerMedDRA version: 6.1Level: PTClassification code 10057654EUCTR2006-000320-14-ITASTRAZENECA512
进行中（未招募）
1 期
Anastrozole monotherapy versus maximal oestrogen blockage with anastrozole and fulvestrant comination therapy: An open, randomised, comparative, phase III multicentre study in postmenopausal women with hormone receptor positive breast cancer in first relapse after primary treatment of localised tumour. - FACTHormone receptor positive breast cancer in first relapse after primary treatment of localised tumour, in postmenopausal women.MedDRA version: 8.1Level: LLTClassification code 10025786Term: Malignant neoplasm of breast (female), unspecifiedEUCTR2006-000320-14-FRAstraZeneca AB512
进行中（未招募）
1 期
Anastrozole monotherapy versus maximal oestrogen blockage with anastrozole and fulvestrant comination therapy: An open, randomised, comparative, phase III multicentre study in postmenopausal women with hormone receptor positive breast cancer in first relapse after primary treatment of localised tumour. - FACTHormone receptor positive breast cancer in first relapse after primary treatment of localised tumour, in postmenopausal women.EUCTR2006-000320-14-FIAstraZeneca oy512
进行中（未招募）
不适用
Anastrozole monotherapy versus maximal oestrogen blockage with anastrozole and fulvestrant comination therapy: An open, randomised, comparative, phase III multicentre study in postmenopausal women with hormone receptor positive breast cancer in first relapse after primary treatment of localised tumour. - FACTHormone receptor positive breast cancer in first relapse after primary treatment of localised tumour, in postmenopausal women.EUCTR2006-000320-14-ISAstraZeneca512
进行中（未招募）
不适用
Anastrozole monotherapy versus maximal oestrogen blockage with anastrozole and fulvestrant combination therapy: An open, randomised, comparative, phase III multicentre study in postmenopausal women with hormone receptor positive breast cancer in first relapse after primary treatment of localised tumour. - FACTHormone receptor positive breast cancer in first relapse after primary treatment of localised tumour, in postmenopausal women.EUCTR2006-000320-14-PTAstraZeneca Produtos Farmacêuticos Lda512